U.S. markets open in 5 hours 50 minutes
  • S&P Futures

    4,108.75
    -10.75 (-0.26%)
     
  • Dow Futures

    33,572.00
    -110.00 (-0.33%)
     
  • Nasdaq Futures

    13,799.75
    -29.75 (-0.22%)
     
  • Russell 2000 Futures

    2,229.30
    -9.90 (-0.44%)
     
  • Crude Oil

    58.83
    -0.49 (-0.83%)
     
  • Gold

    1,739.00
    -5.80 (-0.33%)
     
  • Silver

    25.15
    -0.18 (-0.69%)
     
  • EUR/USD

    1.1884
    -0.0021 (-0.18%)
     
  • 10-Yr Bond

    1.6660
    0.0000 (0.00%)
     
  • Vix

    17.45
    +0.50 (+2.95%)
     
  • GBP/USD

    1.3729
    +0.0023 (+0.17%)
     
  • USD/JPY

    109.4500
    -0.2000 (-0.18%)
     
  • BTC-USD

    61,002.71
    +1,373.68 (+2.30%)
     
  • CMC Crypto 200

    1,315.99
    +88.45 (+7.21%)
     
  • FTSE 100

    6,881.05
    -34.70 (-0.50%)
     
  • Nikkei 225

    29,538.73
    -229.33 (-0.77%)
     

Shattuck Labs Announces Participation in Citi’s 2021 Virtual Immuno-Oncology Day

  • Oops!
    Something went wrong.
    Please try again later.
Shattuck Labs, Inc.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

AUSTIN, TX & DURHAM, NC, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Citi’s 2021 Virtual Immuno-Oncology Day Conference being held virtually February 17-18, 2021.

Presentation Details
Conference: Citi 2021 Virtual Immuno-Oncology Day
Format: Group meeting with Andrew Baum and covering analyst Mohit Bansal
Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, Shattuck’s Vice President of Finance and Corporate Strategy
Date: February 17, 2021
Time: 12:00 p.m. EST
Webcast Link: Available Here

A live webcast will be available at the Events & Presentations section of the Company’s website.

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com